Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:FBRX NASDAQ:GNLX NASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.67-2.0%$10.80$3.39▼$16.00$183.48M0.93502,786 shs273,875 shsFBRXForte Biosciences$14.75-3.4%$12.31$4.11▼$28.68$189.85M3.03107,994 shs66,679 shsGNLXGenelux$5.25+3.6%$3.88$1.99▼$5.89$191.51M-0.22145,946 shs172,644 shsRNXTRenovoRx$1.08-2.7%$1.14$0.75▼$1.69$40.68M1.3783,967 shs490,265 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics0.00%+4.10%+30.99%+184.69%+46.23%FBRXForte Biosciences0.00%-1.42%+44.60%+55.18%+235.60%GNLXGenelux0.00%+13.93%+28.35%+50.00%+94.25%RNXTRenovoRx0.00%-15.91%-13.28%-20.71%+13.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.67-2.0%$10.80$3.39▼$16.00$183.48M0.93502,786 shs273,875 shsFBRXForte Biosciences$14.75-3.4%$12.31$4.11▼$28.68$189.85M3.03107,994 shs66,679 shsGNLXGenelux$5.25+3.6%$3.88$1.99▼$5.89$191.51M-0.22145,946 shs172,644 shsRNXTRenovoRx$1.08-2.7%$1.14$0.75▼$1.69$40.68M1.3783,967 shs490,265 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics0.00%+4.10%+30.99%+184.69%+46.23%FBRXForte Biosciences0.00%-1.42%+44.60%+55.18%+235.60%GNLXGenelux0.00%+13.93%+28.35%+50.00%+94.25%RNXTRenovoRx0.00%-15.91%-13.28%-20.71%+13.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.80Moderate Buy$31.67131.65% UpsideFBRXForte Biosciences 2.50Moderate Buy$68.00361.02% UpsideGNLXGenelux 2.50Moderate Buy$20.33287.30% UpsideRNXTRenovoRx 2.33Hold$7.50594.44% UpsideCurrent Analyst Ratings BreakdownLatest RNXT, GNLX, AVTX, and FBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025RNXTRenovoRxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/29/2025AVTXAvalo TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/27/2025AVTXAvalo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GNLXGeneluxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RNXTRenovoRxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/17/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $25.009/5/2025AVTXAvalo TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/5/2025AVTXAvalo TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K408.55N/AN/A$12.80 per share1.07FBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/AGNLXGenelux$10K19,829.25N/AN/A$0.76 per share6.91RNXTRenovoRx$40K989.55N/AN/A$0.19 per share5.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A-48.48%-35.94%11/6/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)GNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)RNXTRenovoRx-$8.81M-$0.38N/AN/AN/AN/A-120.68%-89.23%11/12/2025 (Estimated)Latest RNXT, GNLX, AVTX, and FBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025AVTXAvalo Therapeutics-$1.67N/AN/AN/AN/AN/A8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/14/2025Q2 2025RNXTRenovoRx-$0.08-$0.08N/A-$0.08$0.25 million$0.42 million8/7/2025Q2 2025AVTXAvalo Therapeutics-$1.43-$1.92-$0.49-$1.92N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A12.4412.44FBRXForte BiosciencesN/A11.7411.74GNLXGeneluxN/A4.184.18RNXTRenovoRxN/A8.618.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%FBRXForte Biosciences77.63%GNLXGenelux37.33%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%FBRXForte Biosciences5.90%GNLXGenelux8.80%RNXTRenovoRx9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4013.15 million13.12 millionNot OptionableFBRXForte Biosciences512.43 million11.70 millionOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableRNXTRenovoRx636.65 million33.30 millionNot OptionableRNXT, GNLX, AVTX, and FBRX HeadlinesRecent News About These CompaniesRenovoRx expands Scientific Advisory Board with appointment of BaereOctober 9, 2025 | msn.comRenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhDOctober 9, 2025 | globenewswire.comRenovoRx announces first patient procedure completed in PanTheR studySeptember 25, 2025 | msn.comRenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical SitesSeptember 25, 2025 | finance.yahoo.comRenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical SitesSeptember 25, 2025 | globenewswire.comRenovoRx’s Earnings Call: Positive Outlook Amid GrowthSeptember 20, 2025 | theglobeandmail.comRenovoRx, Inc. CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025September 11, 2025 | quiverquant.comQRenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16thSeptember 11, 2025 | globenewswire.comDiscovering the Next Wave of Biotech Innovation (MDCX, RNXT, JSPR, LSB)August 22, 2025 | theglobeandmail.comRenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025August 20, 2025 | finance.yahoo.comRenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025August 20, 2025 | businesswire.comRenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | msn.comRenovoRx Revenue Jumps 28 Percent in Q2August 14, 2025 | theglobeandmail.comRenovoRx Reports Strong Q2 2025 Revenue GrowthAugust 14, 2025 | msn.comRenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue EstimatesAugust 14, 2025 | zacks.comRenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data ReviewAugust 14, 2025 | businesswire.comRenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership HireAugust 6, 2025 | globenewswire.comRenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid TumorsJuly 28, 2025 | finance.yahoo.comRenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ETJuly 14, 2025 | businesswire.comInsider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of StockJune 10, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNXT, GNLX, AVTX, and FBRX Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$13.67 -0.28 (-2.01%) Closing price 04:00 PM EasternExtended Trading$13.66 -0.02 (-0.11%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Forte Biosciences NASDAQ:FBRX$14.75 -0.52 (-3.41%) Closing price 04:00 PM EasternExtended Trading$14.74 -0.01 (-0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Genelux NASDAQ:GNLX$5.25 +0.18 (+3.55%) Closing price 04:00 PM EasternExtended Trading$5.58 +0.33 (+6.19%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.RenovoRx NASDAQ:RNXT$1.08 -0.03 (-2.70%) Closing price 04:00 PM EasternExtended Trading$1.10 +0.02 (+2.31%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
